Do Breast Cancer and Irregular Heartbeat Have Common Risk Factors and Rates?

Research Highlights: A new, global analysis finds atrial fibrillation/flutter and breast cancer rates may follow similar risk factors and patterns across regions, particularly among women ages 55 and older. In about 40% of the 204 countries and regions evaluated, the rates of both breast cancer and atrial fibrillation/flutter were similar in older women, with the highest-risk zones in Western nations. Researchers identified modifiable risk factors, particularly alcohol use and smoking, which could substantially reduce the impact of both conditions. DALLAS - July 8, 2026 ( NEWMEDIAWIRE ) - Alcohol use and smoking were linked to breast cancer and atrial fibrillation/flutter in women ages 55 years and older in multiple regions of the world, according to new, independent research published tod

Der Geschäftsbericht von Piramal Pharma für das Geschäftsjahr 2026 unterstreicht die globale Reichweite, das innovationsgetriebene Wachstum und die Meilensteine im Bereich Nachhaltigkeit

MUMBAI, Indien, 8. Juli 2026 /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), ein weltweit führendes Pharma-, Gesundheits- und Wellnessunternehmen, hat seinen Geschäftsbericht für das Geschäftsjahr 2026 veröffentlicht. Dieser hebt ein Jahr hervor, das durch die...

Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors

LONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION ® , a tumor-activated oncology delivery platform, is pleased to announce the appointment of Dr. Patrick Vink, a seasoned healthcare executive, to its Board of Directors as Non-Executive Deputy Chairman and Senior Independent Director.

Le rapport annuel de Piramal Pharma pour l'exercice 2026 souligne l'envergure mondiale de la société, sa croissance axée sur l'innovation et ses avancées majeures en matière de développement durable

MUMBAI, Inde, 8 juillet 2026 /PRNewswire/ -- Piramal Pharma Limited (PPL) (NSE: PPLPHARMA) (BSE: 543635), l'un des leaders mondiaux du secteur pharmaceutique, de la santé et du bien-être, a publié son rapport annuel pour l'exercice 2026, qui met en lumière une année marquée par le...

/C O R R E C T I O N -- Oak Essentials/

In the news release, Oak Essentials Launches the Oak Advisory Council in Honor of Women's Health Month, issued 07-Jul-2026 by Oak Essentials over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows: OAK ESSENTIALS LAUNCHES THE...

Movemedical Launches Ask Move AI, the First AI Assistant Purpose-Built for Med Device Field Operations

Mobile-first AI assistant built on 15+ years of surgical case data gives field reps a conversational interface for every step of their case workflow. SAN DIEGO, July 7, 2026 /PRNewswire/ -- Movemedical, the leading field inventory management platform for the medical device industry, today...

OTR Therapeutics Enters Strategic Collaboration with LG Chem to Accelerate Development of Novel Oncology Therapies

SHANGHAI, July 7, 2026 /PRNewswire/ -- OTR Therapeutics, a clinical-stage biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, today announced that it has entered into a strategic collaboration agreement with LG Chem, a leading global...

SAC Health Acquires Former Rite-Aid Building to Expand Care to the High Desert

SAC Health finalized the purchase of former Rite Aid building in Victorville, California, for a future medical clinic location. SAN BERNARDINO, Calif., July 7, 2026 /PRNewswire-PRWeb/ -- Moving forward with its mission to provide accessible, high-quality healthcare to underserved...

Epidermolysis Bullosa Pipeline 2026: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | RegeneRx Biopharma, BridgeBio Pharma, Berg Pharma, Holostem Terapie

Migraine Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | GlaxoSmithKline, Merck, Pfizer, Bausch Health, Amgen, Abbvie, AstraZeneca, Eli Lilly

Multiple Myeloma Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics, Poseida Therapeutics

Graft vs Host Disease Pipeline 2026: In-depth Clinical Trials Analysis and Emerging Therapies Report by DelveInsight | Cellestia Biotech, Pfizer, Chia Tai Tianqing Pharma, Regimmune Corp